Progyny, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Pete Anevski
- Full Time Employees
- 846
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 1359 Broadway New York City NY United States of America 10018
- IPO Date
- Oct 25, 2019
- CIK
- 0001551306
- Website
- progyny.com
- Similar Companies
- Business
- Progyny, Inc. is a benefits management company specializing in fertility, family building, and women's health benefits solutions in the United States. Founded in 2008 and headquartered in New York City, Progyny offers an integrated suite of products and services that include fertility benefits management; access to a network of top fertility specialists, including reproductive endocrinologists and reproductive urologists; preconception and trying-to-conceive clinical programming and coaching; personalized surrogacy and adoption support; an integrated pharmacy benefits solution (Progyny Rx) providing discounts on fertility medications and patient care; and digital tools with 1:1 member concierge support. The company serves employers, health plans, and benefit purchasers seeking to provide comprehensive reproductive and family-building benefits. Progyny’s offerings extend from preconception through fertility treatments like intrauterine insemination and in vitro fertilization, continuing through pregnancy, postpartum care, menopause, and midlife women’s health support. Recent developments include significant growth during 2024, with the addition of 80 new clients expanding covered lives by 1.1 million. The company achieved its ninth consecutive year of revenue growth, reporting full-year 2024 revenue of $1.17 billion, up 7%, and Q4 revenue growth of 11% year-over-year. Progyny strengthened its market presence with its first-ever national health plan partnership with Cigna, expanding go-to-market reach. It launched new services in maternity, postpartum, and menopause care, which have seen strong adoption. The company continues investing in digital assets and product innovation, positioning for continued growth in 2025 with a forecasted revenue range of $1.175 billion to $1.225 billion. Progyny maintains a high client retention rate of approximately 99%, reflecting strong customer relationships and market leadership in fertility and women's health benefits. Progyny operates primarily in the U.S. market, providing solutions that address the complex needs of fertility and reproductive health through a data-driven, outcomes-focused model. The company’s family building benefit includes financial support and guidance for surrogacy and adoption, distinguishing it as a comprehensive provider that supports diverse paths to parenthood. Progyny's business segments cover fertility benefit services and pharmacy benefits, with recent expansions into broader women's health services. Its integrated approach leverages clinical expertise, technology, and personalized support to optimize clinical outcomes, cost savings, and member experience. Overall, Progyny, Inc. is recognized as a leading provider in fertility and family building benefits, serving a predominantly employer-based clientele within the healthcare benefits industry. Its strategic partnerships, enhanced service offerings, and steady financial growth underscore its role as a transformative player in the reproductive and women’s health benefits sector.
California State Teachers Retirement System Purchases 23,273 Shares of Progyny, Inc. $PGNY
Progyny Inc (PGNY) Stock Down 4.6% -- Now Undervalued? GF Score: 93/100
Boost Your Portfolio Returns With These 4 Top-Ranked Liquid Stocks
Why Progyny Stock Plunged, Then Gradually Recovered Today
Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
Progyny Q2 Earnings Call Highlights
Progyny, Inc. (PGNY) Q2 2026 Earnings Call Transcript
Progyny (PGNY) Reports Q2 Earnings: What Key Metrics Have to Say
Progyny (PGNY) Q2 Earnings and Revenues Beat Estimates
Progyny (PGNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report
Progyny COO Cummings Sells 3,437 Shares for $109,000 -- Here's What That Means for Investors
5 Top Stocks With Relative Price Strength to Buy Right Now
Progyny, Inc. (PGNY) Hit a 52 Week High, Can the Run Continue?
Why Progyny (PGNY) Might be Well Poised for a Surge
Are You Looking for a Top Momentum Pick? Why Progyny (PGNY) is a Great Choice
What Makes Progyny (PGNY) a New Strong Buy Stock
What Does the Sale of Progyny Shares by the CFO Mean for Investors?
A Look at Progyny Inc (PGNY) After 3.8% Gain -- GF Value $28.04 vs Price $26.63
A Progyny (PGNY) Insider Sold 5,500 Shares for $137,000